Home » Stocks » BHVN

Biohaven Pharmaceutical Holding Co. Ltd. (BHVN)

Stock Price: $127.36 USD 3.80 (3.08%)
Updated Jul 28, 2021 4:00 PM EDT - Market closed
Market Cap 8.11B
Revenue (ttm) 106.30M
Net Income (ttm) -858.83M
Shares Out 62.04M
EPS (ttm) -14.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 28
Last Price $127.36
Previous Close $123.56
Change ($) 3.80
Change (%) 3.08%
Day's Open 123.26
Day's Range 122.48 - 127.84
Day's Volume 354,702
52-Week Range 57.66 - 128.37

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW HAVEN, Conn., July 28, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

21 hours ago - PRNewsWire

Migraine sufferers certainly hope so.

Other stocks mentioned: ABBV
1 week ago - The Motley Fool

Biohaven Pharmaceutical's (BHVN) sole approved drug, Nurtec ODT's preliminary sales outperform expectations. Resultantly, share increase 13.6%.

2 weeks ago - Zacks Investment Research

Biohaven Pharmaceutical Ltd. (NYSE:BHVN) released preliminary second-quarter revenue data for its drug Nurtec ODT on Wednesday.

3 weeks ago - Benzinga

Preliminary sales figures for the company's new migraine drug were much better than expected.

3 weeks ago - The Motley Fool

NEW HAVEN, Conn., July 7, 2021 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd.

3 weeks ago - PRNewsWire

TOKYO and CAMBRIDGE, England, June 23, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) today announces that the first healthy subject has been dosed with HTL0022562 in a Phase 1 ...

1 month ago - PRNewsWire

NEW HAVEN, Conn., June 17, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

1 month ago - PRNewsWire

Eli Lilly And Co (NYSE: LLY) will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN) Nurtec ODT (rimeg...

Other stocks mentioned: LLY
1 month ago - Benzinga

CPB, MLAB, TMQ, CGAU, and BHVN have been added to the Zacks Rank #5 (Strong Sell) List on June 14, 2021

Other stocks mentioned: CGAU, CPB, MLAB, TMQ
1 month ago - Zacks Investment Research

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago.

1 month ago - Zacks Investment Research

"This is going to change the paradigm in which migraine is treated," Biohaven Pharmaceutical CEO Vlad Coric said after Nurtec ODT received FDA approval.

1 month ago - CNBC

Biohaven CEO on 'monumental approval' of migraine drug

YouTube video

"We can now say you know that Nurtec ODT is approved for the preventative treatment of migraine," Biohaven CEO Vlad Coric said.

1 month ago - CNBC Television

--(BUSINESS WIRE)--A photo is available on Business Wire's website and the Associated Press Photo Network of Biohaven Pharmaceuticals (NYSE: BHVN) ringing the opening bell, June 8, 2021. BJ Jones, Chief...

1 month ago - Business Wire

NEW HAVEN, Conn., June 3, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

1 month ago - PRNewsWire

The FDA approves Biohaven's (BHVN) Nurtec ODT to prevent migraine besides treating acute migraine attacks.

2 months ago - Zacks Investment Research

The FDA has approved Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN) dissolvable, Nurtec ODT (rimegepant), for preventive treatment in people who experience episodic migraines or fewer than 15 day...

2 months ago - Benzinga

NEW HAVEN, Conn., May 27, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

2 months ago - PRNewsWire

ANIP, BHVN, FVRR, KBAL, and PLNT have been added to the Zacks Rank #5 (Strong Sell) List on May 24, 2021

Other stocks mentioned: ANIP, FVRR, KBAL, PLNT
2 months ago - Zacks Investment Research

MOORESVILLE, N.C., May 14, 2021 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Nurtec® ODT (rimegepant) will be the primary partner for the Rick Ware Racing No.

2 months ago - PRNewsWire

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.

2 months ago - Zacks Investment Research

CHICAGO, May 11, 2021 /PRNewswire/ -- The National Headache Foundation today announced findings from a new survey, Preventing Migraine Attacks: A Current Perspective, which characterizes the experiences...

2 months ago - PRNewsWire

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -44.178% and 0.05%, respectively, for the quarter ended March 2021.

2 months ago - Zacks Investment Research

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -1.71% and 0.05%, respectively, for the quarter ended March 2021.

2 months ago - Zacks Investment Research

Shares of Biohaven Pharma Hldgs (NYSE:BHVN) fell 1.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 24.27% over the past year to ($2.97), which m...

2 months ago - Benzinga

NEW HAVEN, Conn., May 10, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

2 months ago - PRNewsWire

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

2 months ago - Zacks Investment Research

NEW HAVEN, Conn., April 28, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

3 months ago - PRNewsWire

NEW HAVEN, Conn., April 13, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

3 months ago - PRNewsWire

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume.

3 months ago - Zacks Investment Research

NEW HAVEN, Conn., April 7, 2021 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd.

3 months ago - PRNewsWire

MOORESVILLE, N.C., April 6, 2021 /PRNewswire/ -- Rick Ware Racing announced today its partnership with Biohaven's Nurtec® ODT (rimegepant) and Nine Line Apparel to honor the nation's fallen service memb...

3 months ago - PRNewsWire

Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) has enrolled the first patient in a Phase 2/3 trial evaluating oral zavegepant for migraine's preventive treatment, triggering a milestone funding pay...

3 months ago - Benzinga

NEW HAVEN, Conn., March 29, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

3 months ago - PRNewsWire

Biohaven Pharmaceuticals CEO on how Nurtec migraine drug punches above its weight

YouTube video

Biohaven Pharmaceuticals CEO Vlad Coric said the company's digital-first and patient-focused strategy is giving it an edge against competitors in marketing the migraine drug Nurtec.

4 months ago - CNBC Television

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some insiders took advantage of initial public offerings in the past week.

Other stocks mentioned: CPNG, KDP, GOCO, INVA, JOAN, MBIN, PFSI ...
4 months ago - Benzinga

NEW HAVEN, Conn., March 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

4 months ago - PRNewsWire

NEW HAVEN, Conn., March 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

4 months ago - PRNewsWire

Pharmaceutical stocks are a sector with unique success factors. One factor is developing blockbuster drugs.

Other stocks mentioned: ARGX, BMRN, MRTX, NVO, NVS
4 months ago - InvestorPlace

With the trading day halfway over, the broad markets were making yet another strong push.

Other stocks mentioned: ORCL, TSLA, AEP, CATB, ESPR, KDP, QSR ...
4 months ago - 24/7 Wall Street

NEW HAVEN, Conn., March 11, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

4 months ago - PRNewsWire

NEW HAVEN, Conn., March 10, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

4 months ago - PRNewsWire

NEW HAVEN, Conn., March 10, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

4 months ago - PRNewsWire

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

4 months ago - Zacks Investment Research

Agreement enables Biohaven to exercise option on up to three of Artizan's candidates for the treatment of inflammatory bowel disease

4 months ago - GlobeNewsWire

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -25.26% and 0.30%, respectively, for the quarter ended December 2020.

4 months ago - Zacks Investment Research

Shares of Biohaven Pharmaceutical (NYSE:BHVN) decreased 0.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 5.61% year over year to ($2.69), wh...

4 months ago - Benzinga

NEW HAVEN, Conn., March 1, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of ...

4 months ago - PRNewsWire

NEW HAVEN, Conn., Feb. 23, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product...

5 months ago - PRNewsWire

Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN) hyperimmune globulin mimic developed with Biohaven's MATE platform has demonstrated functional binding and neutralization of the SARS-CoV-2 virus, i...

5 months ago - Benzinga

About BHVN

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indi... [Read more...]

Industry
Biotechnology
IPO Date
May 4, 2017
CEO
Vlad Coric
Employees
825
Stock Exchange
NYSE
Ticker Symbol
BHVN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for BHVN stock is "Strong Buy." The 12-month stock price forecast is 118.45, which is a decrease of -7.00% from the latest price.

Price Target
$118.45
(-7.00% downside)
Analyst Consensus: Strong Buy